NEW YORK (GenomeWeb) – Argos Therapeutics announced today that it will collaborate with Personalis to study the mechanism of action of its investigational immuno-oncology drug rocapuldencel-T.

Rocapuldencel-T — formerly AGS-003 — is a personalized immunotherapy based on Argos' Arcelis platform, which uses RNA isolated from a patient sample to program autologous dendritic cells to target only disease-specific antigens. It is being tested in a number of clinical trials, including a Phase III study for metastatic renal cell carcinoma.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.